A personalized CAR-T to attack every solid tumor? Pact Pharma has a plan

Startup Pact Pharma, working with researchers at the University of California, Los Angeles (UCLA), presented new data on a strategy they hope will provide a solution to that problem. The company's approach entails defining specific cancer mutations in each individual patient and then manufacturing an immune-cell therapy that targets abnormal proteins, or “neoantigens,” produced by genes with those mutations.